Africa Malaria Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Malaria diagnostics encompass rapid diagnostic tests (RDTs), microscopy reagents and consumables, nucleic acid amplification-based assays, and emerging molecular and serological platforms. The MEA region accounts for the overwhelming majority of global revenue because sub-Saharan Africa bears roughly 95% of worldwide malaria cases and deaths. Public-sector procurement by ministries of health and global funders such as the Global Fund, PMI, and WHO-coordinated programs anchors demand. Private-sector sales through hospitals, clinics, and community health workers add a smaller but growing commercial layer.

The principal growth driver is the sheer epidemiological burden: hundreds of millions of suspected cases are tested annually across the region, sustaining baseline demand for RDTs and microscopy consumables. International donor financing, including Global Fund replenishments and the U.S. President's Malaria Initiative, underwrites large-volume public procurement and keeps test volumes rising even when donor budgets fluctuate. Rising investment in surveillance, digital reporting, and integration of malaria testing with broader primary-care diagnostics is expanding the role of diagnostic platforms within national health systems.

By technology, the market splits into rapid diagnostic tests (the largest and fastest-growing segment), conventional microscopy (reagents, slides, stains), and molecular diagnostics such as PCR and loop-mediated isothermal amplification (LAMP), which are used mainly for surveillance and outbreak confirmation. By end user, public hospitals, primary-care clinics, community health workers, and a smaller private-laboratory segment account for nearly all consumption. Within MEA, Nigeria, the Democratic Republic of the Congo, Uganda, Mozambique, and Ethiopia together represent the largest national markets, while the Gulf states contribute a relatively small share tied to imported cases and travel medicine.

What are the recent trends and outlook?

The outlook is shaped by the continued rollout of highly sensitive and species-specific RDTs, including tests that detect *Plasmodium falciparum* and *P. vivax*, and growing interest in tests that can identify hrp2/3 deletions linked to diagnostic escape. Molecular point-of-care platforms and digital microscopy with artificial-intelligence-assisted reading are emerging from pilot deployments into routine surveillance use. Demographic growth, urbanisation, and climate-related shifts in transmission zones will keep demand structurally strong, even as the introduction of new malaria vaccines adds a complementary, not competitive, layer to diagnostic use.